Mauritania vs Yemen: HIV/AIDS deaths averted by antiretroviral therapy
Mauritania
277.42 deaths
in 2024
Yemen
267.91 deaths
in 2024
Mauritania rank
103rd
Yemen rank
106th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Mauritania
- Yemen
How they compare
Mauritania currently reports 277.42 deaths against 267.91 deaths in Yemen, a difference of 9.51 deaths.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Yemen ahead.
Mauritania ranks 103rd and Yemen ranks 106th of 157 countries.
Mauritania has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Mauritania | Yemen | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 89.77 deaths | 10.16 deaths | 79.6 deaths | Mauritania |
| 2010s | 261.27 deaths | 127.01 deaths | 134.26 deaths | Mauritania |
| 2020s | 276.93 deaths | 218.27 deaths | 58.66 deaths | Mauritania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Mauritania or Yemen?
- Mauritania, at 277.42 deaths against 267.91 deaths in Yemen as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Mauritania and Yemen?
- 9.51 deaths, with Mauritania ahead.
- How many years of comparable data are there for Mauritania and Yemen?
- 35 years are reported by both, from 1990 to 2024.
- How do Mauritania and Yemen rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Mauritania ranks 103rd and Yemen ranks 106th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.